RYTM Rhythm Pharmaceuticals, Inc.

NASDAQ
$96.77

Rhythm Pharmaceuticals, Inc. (RYTM) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

Insider signal In line Selling ran in line with RYTM's own trailing one-year pace, with 98% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 7 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
9
55 transactions
Purchases
$0
0 shares
Sales
$41.7M
383,926 shares
Net activity
-$41.7M
purchases less sales

How much of that selling was preplanned? 98% planned / 2% discretionary

10b5-1 plan sales $40.8M 53 transactions · 373,669 shares
Discretionary sales $930.9K 2 transactions · 10,257 shares

Largest single sale: $8.9M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Meeker David P 5 fills President and CEO Sell 10b5-1 50,000 $102.67 $5.1M 282,819 −15% of holding
Smith Hunter C 3 fills Chief Financial Officer Sell 10b5-1 62,774 $105.46 $6.6M 153,726 −29% of holding
Lee Jennifer Kayden EVP, Head of North America Sell 10b5-1 75,834 $117.38 $8.9M None left
Garfield Alastair 4 fills Chief Scientific Officer Sell 10b5-1 7,763 $117.57 $912.7K 8,051 −49.1% of holding
Shulman Joseph Chief Technical Officer Sell 10b5-1 5,079 $119.75 $608.2K 15,915 −24.2% of holding
Mazabraud Yann 6 fills EVP, Head of International Sell 10b5-1 57,000 $116.15 $6.6M 110,355 −34.1% of holding
TETRAULT LYNN A. Director Sell 10b5-1 37,000 $100.32 $3.7M 7,000 −84.1% of holding
German Christopher Paul Corporate Controller & CAO Sell 4,643 $92.21 $428.1K None left
German Christopher Paul Corporate Controller & CAO Sell 5,614 $89.56 $502.8K 160 −97.2% of holding
Smith Hunter C 4 fills Chief Financial Officer Sell 10b5-1 4,385 $101.26 $444.0K 113,589 −3.7% of holding
Smith Hunter C 5 fills Chief Financial Officer Sell 10b5-1 3,569 $101.38 $361.8K 117,266 −3% of holding
Smith Hunter C 4 fills Chief Financial Officer Sell 10b5-1 1,592 $98.23 $156.4K 119,766 −1.3% of holding
Smith Hunter C 3 fills Chief Financial Officer Sell 10b5-1 2,766 $98.61 $272.8K 120,558 −2.2% of holding
Smith Hunter C 3 fills Chief Financial Officer Sell 10b5-1 2,713 $103.00 $279.4K 123,624 −2.1% of holding
Smith Hunter C Chief Financial Officer Sell 10b5-1 3,381 $106.06 $358.6K 125,537 −2.6% of holding
Smith Hunter C 3 fills Chief Financial Officer Sell 10b5-1 3,247 $105.99 $344.1K 130,665 −2.4% of holding
Cramer Pamela J. Chief Human Resources Officer Sell 10b5-1 3,350 $111.00 $371.9K 20,814 −13.9% of holding
Cramer Pamela J. Chief Human Resources Officer Sell 10b5-1 3,350 $105.00 $351.8K 20,814 −13.9% of holding
Cramer Pamela J. Chief Human Resources Officer Sell 10b5-1 3,515 $100.00 $351.5K 20,814 −14.4% of holding
Cramer Pamela J. Chief Human Resources Officer Sell 10b5-1 19,351 $98.82 $1.9M 20,814 −48.2% of holding
Shulman Joseph Chief Technical Officer Sell 10b5-1 9,748 $115.24 $1.1M 8,509 −53.4% of holding
Shulman Joseph Chief Technical Officer Sell 10b5-1 2,815 $115.01 $323.8K 8,509 −24.9% of holding
Shulman Joseph 3 fills Chief Technical Officer Sell 10b5-1 14,437 $112.03 $1.6M 20,253 −41.6% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.